Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Lancet (London, England)|June 12, 2022
Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databasesHui-Lee Wong, Mao Hu, Cindy Ke Zhou, et al.
JAMA Pediatrics|May 22, 2023
Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 YearsMao Hu, Hui Lee Wong, Yuhui Feng, et al.
Pharmacoepidemiology and Drug Safety|May 6, 2025
Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United StatesPatricia C Lloyd, Elizabeth R Smith, Joann F Gruber, et al.
Vaccine|August 22, 2025
Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series analysesPatricia C Lloyd, Gyanada Acharya, Henu Zhao, et al.
JAMA Network Open|April 24, 2024
Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 YearsMao Hu, Azadeh Shoaibi, Yuhui Feng, et al.
Vaccine|February 22, 2024
Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020Patricia C Lloyd, Bradley Lufkin, Keran Moll, et al.
Vaccine: X|February 6, 2024
Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United StatesJ Bradley Layton, Lauren Peetluk, Hui Lee Wong, et al.
BMC Pediatrics|April 26, 2024
Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort studyRachel P Ogilvie, J Bradley Layton, Patricia C Lloyd, et al.
Plos One|May 6, 2025
Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United StatesJ Bradley Layton, Patricia C Lloyd, Lauren S Peetluk, et al.
Vaccine|November 20, 2022
Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020Keran Moll, Bradley Lufkin, Kathryn R Fingar, et al.
Pageof 17